https://www.selleckchem.com/products/mm3122.html
039) Secukinumab and ixekizumab have demonstrated high efficacy and safety, with no statistically significant differences. © 2020 Wiley Periodicals, Inc.OBJECTIVE To compare the duration (hours until HCO 3 - ≥ 15 mmol/L) of diabetic ketoacidosis (DKA) episodes that are the first manifestation of new type 1 diabetes (NT1D) and those that are a complication in patients with previously diagnosed type 1 diabetes (PT1D). METHODS A multicenter retrospective cohort study was designed. The duration of DKA was measured from the start of the trea
Like
Comment
Share
